Invention Grant
- Patent Title: Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
-
Application No.: US15576351Application Date: 2016-05-31
-
Publication No.: US10174037B2Publication Date: 2019-01-08
- Inventor: Dong-Ming Shen , Michael P. Dwyer , Christopher J. Sinz , Deping Wang , Shawn J. Stachel , Daniel V. Paone , Ashley Forster , Richard Berger , Yili Chen , Yimin Qian , Shimin Xu , Chunmei Hu
- Applicant: Merck Sharp & Dohme Corp. , MSD R & D (China) Co., LTD.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; John C. Todaro
- Priority: WOPCT/CN2015/080784 20150604
- International Application: PCT/US2016/034928 WO 20160531
- International Announcement: WO2016/196417 WO 20161208
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61P25/28 ; A61P25/22 ; A61P25/18 ; A61P25/16 ; A61P25/06
Abstract:
The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Public/Granted literature
- US20180148453A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS Public/Granted day:2018-05-31
Information query
